Skip to main content
Top
Published in: Intensive Care Medicine 12/2016

01-12-2016 | What's New in Intensive Care

Alternatives to antibiotics

Authors: Bruno François, Hasan S. Jafri, Marc Bonten

Published in: Intensive Care Medicine | Issue 12/2016

Login to get access

Excerpt

Infection remains one of the main reasons for admission to intensive care units (ICU). As a consequence, more than 60 % of ICU patients receive antibiotics during their stay in the ICU [1], despite implementation of antibiotic stewardship programs to improve the quality of antibiotic use [2, 3]. In most countries antibiotic consumption is mainly driven by pulmonary infections, such as community acquired pneumonia (CAP), healthcare associated pneumonia (HCAP), hospital acquired pneumonia (HAP), and ventilator associated pneumonia (VAP). Bacterial resistance has concurrently increased, especially for Gram negative bacilli, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii, while prevalence of methicillin resistance among Staphylococcus aureus has remained stable or declined in most European countries [4]. Yet, very few new antibiotics have been developed over the past decade and only a few novel drugs are in the development pipeline of pharmaceutical companies. To meet the current and emerging unmet medical needs, alternative therapeutic options to antibiotics, including new strategies, have to be considered in the ICU. Among the several non-antibiotic strategies that are currently being investigated in the ICU, we focused on monoclonal antibodies and bacteriophages but some others such as vaccination, immune stimulation, antibacterial peptide, or probiotics could also bring encouraging results in the near future [5]. …
Literature
1.
go back to reference Bergmans DC, Bonten MJ, Gaillard CA, van Tiel FH, van der Geest S, de Leeuw PW, Stobberingh EE (1997) Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother 39:527–535CrossRefPubMed Bergmans DC, Bonten MJ, Gaillard CA, van Tiel FH, van der Geest S, de Leeuw PW, Stobberingh EE (1997) Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother 39:527–535CrossRefPubMed
2.
go back to reference Allerberger F, Gareis R, Jindrak V, Struelens MJ (2009) Antibiotic stewardship implementation in the EU: the way forward. Expert Rev Anti Infect Ther 7:1175–1183CrossRefPubMed Allerberger F, Gareis R, Jindrak V, Struelens MJ (2009) Antibiotic stewardship implementation in the EU: the way forward. Expert Rev Anti Infect Ther 7:1175–1183CrossRefPubMed
3.
go back to reference Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society (2012) Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 33:322–327CrossRef Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society (2012) Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 33:322–327CrossRef
5.
go back to reference Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA et al (2016) Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis 16(2):239–251CrossRefPubMed Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA et al (2016) Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis 16(2):239–251CrossRefPubMed
6.
go back to reference Timsit JF, Perner A, Bakker J, Bassetti M, Benoit D, Cecconi M et al (2015) Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Med 41(4):575–588CrossRefPubMedPubMedCentral Timsit JF, Perner A, Bakker J, Bassetti M, Benoit D, Cecconi M et al (2015) Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Med 41(4):575–588CrossRefPubMedPubMedCentral
7.
go back to reference Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT et al (2013) Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 13(8):665–671CrossRefPubMed Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT et al (2013) Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 13(8):665–671CrossRefPubMed
8.
go back to reference Que Y, Lazar H, Wolff M, Francois B, Laterre PF, Mercier E, Garbino J, Pagani JL, Revelly JP, Mus E, Perez A, Tamm M, Rouby JJ, Lu Q, Chastre J, Eggimann P (2014) Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 33(10):1861–1867CrossRefPubMed Que Y, Lazar H, Wolff M, Francois B, Laterre PF, Mercier E, Garbino J, Pagani JL, Revelly JP, Mus E, Perez A, Tamm M, Rouby JJ, Lu Q, Chastre J, Eggimann P (2014) Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 33(10):1861–1867CrossRefPubMed
9.
go back to reference Francois B, Luyt CE, Dugard A, Wolff M, Diehl J, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J (2012) Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 40(8):2320–2326CrossRefPubMed Francois B, Luyt CE, Dugard A, Wolff M, Diehl J, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J (2012) Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 40(8):2320–2326CrossRefPubMed
10.
go back to reference DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK (2014) A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6(262):262ra155CrossRefPubMed DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK (2014) A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6(262):262ra155CrossRefPubMed
11.
go back to reference Berube BJ, Bubeck Wardenburg J (2013) Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel) 5(6):1140–1166CrossRef Berube BJ, Bubeck Wardenburg J (2013) Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel) 5(6):1140–1166CrossRef
12.
go back to reference Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR et al (2015) Quality and safety requirements for sustainable phage therapy products. Pharm Res 32:2173–2179CrossRefPubMedPubMedCentral Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR et al (2015) Quality and safety requirements for sustainable phage therapy products. Pharm Res 32:2173–2179CrossRefPubMedPubMedCentral
13.
go back to reference Sansom C (2015) Phage therapy for severe infections tested in the first multicentre trial. Lancet Infect Dis 15(12):1384–1385CrossRefPubMed Sansom C (2015) Phage therapy for severe infections tested in the first multicentre trial. Lancet Infect Dis 15(12):1384–1385CrossRefPubMed
14.
go back to reference Coulter LB, McLean RJ, Rohde RE, Aron GM (2014) Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses 6(10):3778–3786CrossRefPubMedPubMedCentral Coulter LB, McLean RJ, Rohde RE, Aron GM (2014) Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses 6(10):3778–3786CrossRefPubMedPubMedCentral
15.
go back to reference Shaw KJ, Lehman SM, Smrekar F, Weiss WJ, Pulse M, Morales SP (2015) Efficacy of a bacteriophage cocktail in a Staphylococcus aureus mouse pneumonia model is comparable to vancomycin. Poster presentation, ICAAC/ICC 2015, San Diego Shaw KJ, Lehman SM, Smrekar F, Weiss WJ, Pulse M, Morales SP (2015) Efficacy of a bacteriophage cocktail in a Staphylococcus aureus mouse pneumonia model is comparable to vancomycin. Poster presentation, ICAAC/ICC 2015, San Diego
16.
go back to reference Cooper CJ, Denyer SP, Maillard JY (2014) Stability and purity of a bacteriophage cocktail preparation for nebulizer delivery. Lett Appl Microbiol 58:118–122CrossRefPubMed Cooper CJ, Denyer SP, Maillard JY (2014) Stability and purity of a bacteriophage cocktail preparation for nebulizer delivery. Lett Appl Microbiol 58:118–122CrossRefPubMed
17.
go back to reference Sahota JS, Smith CM, Radhakrishnan P, Winstanley C, Goderdzishvili M, Chanishvili N, Kadioglu A, O’Callaghan C, Clokie MR (2015) Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv 28(5):353–360CrossRefPubMed Sahota JS, Smith CM, Radhakrishnan P, Winstanley C, Goderdzishvili M, Chanishvili N, Kadioglu A, O’Callaghan C, Clokie MR (2015) Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv 28(5):353–360CrossRefPubMed
Metadata
Title
Alternatives to antibiotics
Authors
Bruno François
Hasan S. Jafri
Marc Bonten
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 12/2016
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-016-4339-y

Other articles of this Issue 12/2016

Intensive Care Medicine 12/2016 Go to the issue

Correspondence

You neglected a few